Semaglutide Injectable Telehealth Online Consult By mimicking this hormone (GLP-1), it targets the area of the brain that regulates our appetite and food consumption
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist primarily approved by the FDA for type 2 diabetes management, chronic weight management, and cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity
Diet, exercise, sleep, and stress management all influence outcomes
Similarly, patent holders, like Novo Nordisk, do not hold a patent on the ingredients contained in an FDA-approved therapy, only the FDA-approved medication itself
Clinical practice typically involves using statins as the foundation of lipid management, with GLP-1 receptor agonists added when indicated for diabetes or weight management
Semaglutide can only be obtained with a valid prescription from a licensed healthcare provider